-- Financing supports building immunology and inflammation pipeline, advancing lead programs into the clinic and ongoing development of the Attobody platform -- Attovia’s lead programs include potential first-in-class, long half-life anti-IL31 (ATTO-1310) and bispecific anti-IL31 x IL13 (ATTO-002) for the treatment of inflammatory dermatologic diseases FREMONT, Calif., Feb.

--资金支持建立免疫学和炎症管道，将领先项目推进临床和Attobody平台的持续开发-Attovia的领先项目包括潜在的一流，长半衰期抗IL31（ATTO-1310）和双特异性抗IL31 x IL13（ATTO-002），用于治疗炎症性皮肤病，加利福尼亚州弗里蒙特，2月。

08, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics, a biotech company pioneering spatially optimized biparatopic biologics, announced the closing of the $30 million second tranche of its previously reported $60 million Series A financing. Attovia also announced the nomination of the first development candidate generated from its Attobody™ biologics platform, ATTO-1310, a potential first-in-class, long half-life anti-IL31 Attobody.

2024年8月8日（环球通讯社）--生物技术公司Attovia Therapeutics是一家开创空间优化的biparatopic biologics的公司，宣布关闭其先前报告的6000万美元a系列融资的3000万美元第二部分。Attovia还宣布提名其Attobody™生物制剂平台产生的第一个开发候选人ATTO-1310，这是一种潜在的一流的长半衰期抗IL31 Attobody。

Proceeds from the second tranche will be used to advance ATTO-1310 through early clinical trials, move the Company’s second program, ATTO-002, a bispecific IL31 x IL13 ligand trap, toward IND-enabling studies, and to further develop the Attobody platform and early discovery pipeline. “The novel advantages of the biparatopic binding mode of the Attobody technology include potential for higher efficacy and the ability to expand the universe of druggable epitopes,” said Tao Fu, CEO of Attovia.

第二部分的收益将用于通过早期临床试验推进ATTO-1310，将公司的第二个计划ATTO-002（一种双特异性IL31 x IL13配体陷阱）推向IND使能研究，并进一步开发Attobody平台和早期发现管道。Attovia首席执行官陶福（Tao Fu）表示：“Attobody技术的双主题结合模式的新优势包括具有更高功效的潜力和扩大可药物表位范围的能力。”。

“Our first set of programs validate the Attobody platform and illustrate Attovia’s core capabilities to discover and develop small format biologics with first- or best-in-class potential at industry-leading speed. In just eight months, the Attovia team has successfully closed both tranches of the $60 million Series A financing, built a pipeline of five novel programs, and rapidly advanced our lead programs towards the clinic.

“我们的第一套计划验证了Attobody平台，并说明了Attovia以业界领先的速度发现和开发具有一流或一流潜力的小型生物制剂的核心能力。在短短八个月的时间里，Attovia团队成功完成了6000万美元A系列融资的两部分，建立了五个新颖计划的管道，并迅速推进了我们的带领项目走向诊所。

I am thrilled to partner with our investors, executive team, .

我很高兴能与我们的投资者、管理团队合作。